Anthocyanin supplementation in alleviating thrombogenesis in overweight and obese population: A randomized, double-blind, placebo-controlled study. (May 2017)

• Record Type: Journal Article
• Authors: Thompson, Kiara; Pederick, Wayne; Singh, Indu; Santhakumar, Abishek Bommannan
• Is Part Of: Journal of functional foods. Volume 32(2017)
• Page Start: 131
• Page End: 138
• Publication Date: 2017-05
• Subjects: ACN/s anthocyanin/s -- APTT activated partial thromboplastin time -- ADP adenosine diphosphate -- PE-Cy7 allophycocyanin-cyanine 7 -- APC allophycocyanin -- ANOVA analysis of variance -- BMI body mass index -- CVD cardiovascular disease -- COX-1 cyclooxygenase-1 -- EDTA ethylenediaminetetraacetic acid -- FDP fibrinogen degradation product -- FITC fluorescein isothiocyanate -- FBC full blood count -- HDL high-density lipoprotein -- LDL low-density lipoprotein -- mAb monoclonal Antibodies -- PBO placebo -- PE phycoerythrin -- PECAM-1 platelet endothelial cell adhesion molecule-1 -- PRP platelet-rich plasma -- PAC-1 Procaspase-1 -- PT prothrombin time -- QC Quality Control -- QGPJ Queen Garnett Plum Juice -- RCPA Royal College of Pathologists Australia -- SST serum separate tube -- SD standard deviation; Thrombosis -- Anthocyanin -- Obesity -- Platelet function -- Polyphenols; Functional foods -- Analysis -- Periodicals; Food -- Biotechnology -- Periodicals; Nutrition -- Periodicals; 613.2
• DOI: 10.1016/j.jff.2017.02.031
• Languages: English
• ISSNs: 1756-4646

Abstract

Highlights: Anthocyanins reduce platelet aggregation in obese/overweight population. Anthocyanins alleviate platelet activation-dependant surface marker expression. Anthocyanins modulate mechanisms involved in thrombogenesis. Anthocyanins displays potential as a complementary antiplatelet therapeutic. Abstract: The aim was to evaluate the effect of anthocyanin (ACN) supplementation in reducing thrombogenesis and maintaining hemostasis in pro-thrombotic overweight and obese individuals. Twenty-six (M = 9, F = 17) overweight/obese (BMI > 25) individuals participated in this randomized, double-blind, placebo-controlled, crossover design dietary intervention trial. Volunteers consumed ACN (320 mg/day) or placebo capsules for 28-days followed by a two-week wash-out period. ACN supplementation inhibited adenosine diphosphate (ADP)-induced platelet activation-related conformational change and degranulation by reducing PAC-1 expression by 12% and P-selectin expression by 9% respectively. ACN supplementation also alleviated thrombogenic progression by reducing monocyte-platelet aggregate formation by 29% and platelet endothelial cell adhesion molecule-1 (PECAM-1) expression by 21%. Platelet aggregation induced by ADP, collagen and arachidonic acid was reduced by 36%, 17%, and 24% respectively. ACN supplementation has the potential to reduce the risk of thrombosis in overweight/obese population by targeting specific pathways of platelet activation/aggregation and endothelial dysfunction associated leucocyte migration.